Dabigatran versus Warfarin in Patients with Atrial Fibrillation
Key result
Dabigatran 150 mg reduced stroke and systemic embolism rates compared to warfarin, while major hemorrhage rates remained similar.
Why the study?
Does dabigatran reduce stroke and systemic embolism in patients with atrial fibrillation compared to warfarin?
Population
Patients with atrial fibrillation
Comparison
Dabigatran (110 mg or 150 mg) vs Warfarin
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
May support dabigatran 150 mg as warfarin alternative in AF; leaves open confirmation in larger trials.
Structured PICO
Does dabigatran reduce stroke and systemic embolism in patients with atrial fibrillation compared to warfarin?
P
Population
Patients with atrial fibrillation
I
Intervention
Dabigatran (110 mg or 150 mg)
C
Comparator
Warfarin
O
Outcome
Stroke and systemic embolismhard clinical
Dabigatran offers a dose-dependent alternative to warfarin in atrial fibrillation, with the 150 mg dose improving efficacy without increasing major bleeding, and the 110 mg dose reducing bleeding with similar efficacy.
Cite This Study
Connolly et al. (2009) studied this question. Dabigatran 150 mg reduced stroke and systemic embolism rates compared to warfarin, while major hemorrhage rates remained similar.